## Edgar Filing: TITAN PHARMACEUTICALS INC - Form 4

TITAN PHA Form 4 February 02,	RMACEUTICA 2016	LS INC									
FORM	-	PPROVAL									
	UNITED	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								7	
Check thi if no long subject to Section 14 Form 4 of	6.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							Expires: January 31, 2005 Estimated average burden hours per response 0.5		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type R	Responses)										
1. Name and A Rubin Marc	Person <sup>*</sup>	2. Issuer Name <b>and</b> Ticker or Trading 5. Relati Symbol Issuer					onship of Reporting Person(s) to				
		TITAN PHARMACEUTICALS IN [TTNP]				(Check all applicable)					
(Last)	3. Date of Earliest Transaction (Month/Day/Year)			X_ Director 10% Owner X_ Officer (give title Other (specify below)							
BLVD.,, SU			02/02/2016				Exe	Executive Chairman			
	4. If Amendment, Date Original Filed(Month/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> </ul>							
SO. SAN FF	RANCISCO, CA	94080					Form filed by Person	More than One R	eporting		
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Rep	ort on a separate line	for each cl	ass of sec	urities bene	ficially ow	ned directly of	or indirectly.				
					inforn requii	nation cont red to respo iys a curre	spond to the colle ained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		
	Tab					posed of, or convertible :	Beneficially Owner securities)	đ			

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transact	ionDerivative	Expiration Date	Underlying Securities

## Edgar Filing: TITAN PHARMACEUTICALS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code Securities (Instr. 8) Acquired (A) or Disposed o (D) (Instr. 3, 4, and 5)		(A) ed of	(Month/Day/Year) f		(Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	\$ 5.1	02/02/2016		А	79,100		<u>(1)</u>	02/02/2026	Common Stock	79,100

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>		Relationships						
	Director	10% Owner	Officer	Other				
Rubin Marc 400 OYSTER POINT BLVD., SUITE 505 SO. SAN FRANCISCO, CA 9408	X 0		Executive Chairman					
Signatures								
/s/ Marc Rubin 02/02	/2016							

<u>\*\*</u>Signature of Reporting Person

Date

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The options vest in 24 equal monthly installments commencing on the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.